Prosecution Insights
Last updated: April 19, 2026

Renascience Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
3
Final Rejections
0
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17925750 DRUG FOR ENHANCING FIBRINOLYTIC SYSTEM, AND USE THEREFOR SCHMITT, MICHAEL J 1629 Final Rejection Apr 28, 2023
17764312 INHIBITOR AGAINST EXPRESSION OF IMMUNE CHECKPOINT MOLECULE AEDER, SEAN E 1642 Final Rejection Jun 29, 2022
17441484 ORALLY ACTIVE SMALL MOLECULE INHIBITOR OF PAI-1 HEITMEIER, KENDALL NICOLE 1621 Final Rejection Sep 21, 2021

Managing Renascience Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month